The influence of the acetylator phenotype for the clinical use of dihydralazine.
Dihydralazine is a substrate of the human N-acetyltransferase. Therefore the acetylator phenotype could influence the pharmacodynamic response of dihydralazine and/or side effects of this drug. In this study it could be shown that: among patients with dihydralazine incompatibility slow acetylators preponderated; the risk of early side effects was higher in females than in males; and the ratio of fast/slow acetylators was higher in dihydralazine treated patients than in patients treated with other antihypertensives. Dihydralazine should be given very cautiously to female hypertonic patients that are slow acetylators.
D000107:Acetylation; D000328:Adult; D004078:Dihydralazine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000031:analogs & derivatives*; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D012189:Retrospective Studies
D006830:Hydralazine; D004078:Dihydralazine